#1 Clinical Trials Search in Europe

Brimonidine

Brimonidine, a medication used in various ophthalmic formulations, has been the subject of numerous clinical trials investigating its efficacy in treating a range of eye conditions. These studies have explored different concentrations and applications of brimonidine, from reducing ocular redness to managing symptoms of ocular graft-versus-host disease. This article summarizes key findings from recent clinical trials, highlighting the potential benefits and diverse uses of brimonidine in ophthalmology.

Table of Contents

What is Brimonidine?

Brimonidine is a medication that belongs to a class of drugs called alpha-2 adrenergic agonists. It is primarily used in ophthalmology (eye medicine) for various conditions. Brimonidine is known by several brand names, including Alphagan-P, Mirvaso, and Lumify, depending on its concentration and specific use[1][2].

Conditions Treated with Brimonidine

Brimonidine is used to treat several eye-related conditions:

  • Glaucoma: Brimonidine is commonly used to lower intraocular pressure (pressure inside the eye) in patients with open-angle glaucoma or ocular hypertension[3].
  • Rosacea: A topical gel form of brimonidine (Mirvaso) is approved for treating facial erythema (redness) associated with rosacea in adults[4].
  • Eye Redness: Over-the-counter brimonidine eye drops (Lumify) are used to relieve eye redness due to minor eye irritations[5].
  • Ocular Graft-vs-Host Disease (oGVHD): Research is ongoing to evaluate brimonidine’s effectiveness in treating this condition, which can occur after bone marrow transplants[1].

How Brimonidine Works

Brimonidine works in different ways depending on its use:

  • For glaucoma, it reduces the production of aqueous humor (the clear fluid inside the eye) and increases its outflow, thereby lowering intraocular pressure[6].
  • For rosacea and eye redness, brimonidine acts as a vasoconstrictor, narrowing blood vessels in the eye or skin to reduce redness[7].
  • In oGVHD, brimonidine may help relieve inflammation and dryness associated with the condition[8].

Forms and Dosages

Brimonidine comes in several forms and concentrations:

  • Eye drops: Available in concentrations of 0.1%, 0.15%, and 0.2% for glaucoma treatment[6].
  • Over-the-counter eye drops: 0.025% concentration for relieving eye redness[5].
  • Topical gel: 0.33% concentration for facial redness in rosacea[4].

The dosage and frequency of application depend on the condition being treated and should be determined by a healthcare professional.

Ongoing Research and Potential New Uses

Researchers are exploring new potential uses for brimonidine:

  • Hand-Foot Syndrome: A study is investigating whether topical brimonidine can reduce symptoms of hand-foot syndrome, a side effect of some cancer treatments[9].
  • Pterygium Surgery: Brimonidine is being studied for its potential to reduce bleeding during eye surgery for pterygium, a growth on the eye’s surface[2].
  • Presbyopia: Brimonidine is being investigated as part of a combination eye drop treatment for presbyopia, an age-related condition affecting near vision[10].

Potential Side Effects

Like all medications, brimonidine can cause side effects. Common side effects may include:

  • Eye irritation, burning, or stinging
  • Dry eyes
  • Blurred vision
  • Headache
  • Drowsiness

Less common but more serious side effects can include allergic reactions, changes in heart rate or blood pressure, and worsening of depression. It’s important to discuss any side effects with your healthcare provider[1].

Condition Brimonidine Formulation Key Findings
Ocular Redness Brimonidine tartrate 0.025% with sodium hyaluronate Compared to Lumify for efficacy in treating ocular redness
Hand-foot Syndrome Brimonidine 3 mg/g gel Potential preventive effect on severity of HFS symptoms in cancer patients
Chronic Persistent Vascular Facial Erythema Mirvaso® gel (5 mg/g brimonidine tartrate) Evaluated efficacy after 4 weeks of treatment
Rosacea Brimonidine topical gel, 0.33% Assessed signs and symptoms of rosacea, including erythema
Ocular Graft-vs-Host Disease (oGVHD) Brimonidine 0.15% and 0.075% eye drops Evaluated tolerability and preliminary efficacy in treating Meibomian Gland Dysfunction
Pterygium Surgery Brimonidine tartrate 0.15% and 0.025% Assessed effect on reducing subconjunctival hemorrhage during surgery
Ocular Graft-vs-Host Disease (oGVHD) Brimonidine tartrate nanoemulsion eye drops 0.18% Evaluated safety and efficacy in treating oGVHD symptoms

FAQ

  • What is brimonidine and how does it work? Brimonidine is a selective alpha-2 adrenergic agonist used in ophthalmology. It works by constricting blood vessels in the eye, which can reduce redness, inflammation, and intraocular pressure. Different formulations and concentrations are used for various eye conditions.
  • What conditions can brimonidine treat? Clinical trials have investigated brimonidine for treating ocular redness, dry eye disease, ocular graft-versus-host disease (oGVHD), glaucoma, and reducing subconjunctival hemorrhage during eye surgeries. It has also been studied for its potential in managing hand-foot syndrome in cancer patients.
  • How is brimonidine typically administered? Brimonidine is usually administered as eye drops. The frequency of application varies depending on the condition being treated and the concentration of the solution. In clinical trials, it has been used from once daily to four times daily.
  • Are there any side effects associated with brimonidine use? Common side effects may include eye irritation, dryness, or redness. Some patients may experience blurred vision, headache, or fatigue. In most cases, side effects are mild and self-limiting. However, it's important to consult with a healthcare provider about potential risks.
  • How effective is brimonidine in treating ocular conditions? Clinical trials have shown promising results for brimonidine in various ocular conditions. For example, it has demonstrated effectiveness in reducing ocular redness, improving symptoms of dry eye disease, and managing oGVHD. However, effectiveness can vary depending on the specific condition and individual patient factors.

Ongoing Clinical Trials on Brimonidine

  • Study on Glaucoma Treatment: Comparing Brimonidine, Pilocarpine Nitrate, and Brinzolamide in Patients with Newly Diagnosed Open-Angle Glaucoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Sweden

Glossary

  • Ocular Graft-versus-Host Disease (oGVHD): A complication that can occur in patients who have undergone allogeneic bone marrow transplants, resulting in inflammation and damage to the ocular surface and tear-producing glands.
  • Meibomian Gland Dysfunction (MGD): A condition where the oil-producing glands in the eyelids become clogged or don't function properly, leading to dry eye symptoms and ocular discomfort.
  • Subconjunctival Hemorrhage: Bleeding underneath the conjunctiva, the clear membrane covering the white part of the eye, often appearing as a bright red patch on the eye.
  • Intraocular Pressure (IOP): The fluid pressure inside the eye, which is important in the diagnosis and management of glaucoma.
  • Erythema: Redness of the skin or mucous membranes caused by increased blood flow to superficial capillaries.
  • Hyperemia: An excess of blood in the vessels supplying an organ or other part of the body, often visible as redness in the eyes.
  • Nanoemulsion: A mixture of two immiscible liquids, where one liquid is dispersed as very small droplets within the other, used to improve drug delivery and absorption.
  • Pterygium: A growth of the conjunctiva or mucous membrane that covers the white part of the eye over the cornea.
  • Validated Bulbar Redness (VBR) Score: A standardized scale used to assess the degree of redness in the white part of the eye, ranging from 10 (least redness) to 100 (most redness).
  • Visual Analog Scale (VAS): A measurement instrument used to assess subjective characteristics or attitudes that cannot be directly measured, often used for pain or discomfort assessment.

References

  1. https://clinicaltrials.gov/study/NCT02975557
  2. https://clinicaltrials.gov/study/NCT04683159
  3. https://clinicaltrials.gov/study/NCT00347035
  4. https://clinicaltrials.gov/study/NCT02249065
  5. https://clinicaltrials.gov/study/NCT02039765
  6. https://clinicaltrials.gov/study/NCT00352807
  7. https://clinicaltrials.gov/study/NCT02856919
  8. https://clinicaltrials.gov/study/NCT03591874
  9. https://clinicaltrials.gov/study/NCT03173365
  10. https://clinicaltrials.gov/study/NCT05656027